The Oxford Science Park appoints Jitesh Patel as Development Manager

Oxford, UK, January 19 2022 - The Oxford Science Park, one of the UK's leading parks for science and technology companies, has appointed experienced property developer Jitesh Patel to the new role of Development Manager. He will play an important role in delivering the Park’s accelerated development schedule driven by last year’s strategic partnership between Magdalen College and GIC. Jitesh joins from Kajima Partnerships where he worked on a variety of projects valued in excess of £200m, including health care centres and housing. He has a MSc in Facilities Management and BSc in Building Surveying.

Magdalen College Oxford, owner of The Oxford Science Park, and an affiliate of GIC entered into the strategic partnership in October 2021 to accelerate the development of Park. The multi-building development plan at TOSP will accommodate strong demand and future growth requirements of leading science and technology companies. Several state-of-the-art facilities are planned for TOSP’s 23 gross acres of development land, with the capacity to add at least a further 500,000 sq ft.

‘The Oxford Science Park’s exciting and ambitious development plans will cement its position as a leading location for innovative science and technology companies. Having worked in Oxfordshire earlier in my career, I’m delighted to return to help TOSP deliver on this vision.’, Jitesh Patel, Development Manager at TOSP, commented on his appointment.

Rory Maw, CEO of The Oxford Science Park, said, ‘We are delighted to appoint Jitesh to the new role of Development Manager as the Park continues to evolve. His expertise in leading complex construction and property development projects make him the ideal addition to our enlarged team.’


More news and updates

BIA celebrates RQ BIO licencing agreement with AstraZeneca for monoclonal antibodies targeted at COVID-19

Today RQ BIO has announced a licencing agreement with AstraZeneca for its portfolio of early-stage monoclonal antibodies targeted against SARS-CoV-2, with the company also emerging from stealth mode on completion of the agreement. RQ Bio is a UK-based biotechnology company focused on developing treatments and preventative therapies based on potent broad-spectrum mAbs to address areas of unmet need in vulnerable patient populations.

Coulter Partners places Chief Operating Officer at Treadwell Therapeutics, playing an integral role in the company’s evolution

Coulter Partners, the global experts in Executive Search and Leadership Development in Life Sciences, Health, and Tech, recently partnered with Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, and are pleased to announce the placement of J.D. Mowery as Chief Operating Officer (COO).

Innovation community at The Oxford Science Park expands further as companies move into the Hayakawa Building

The innovation community at The Oxford Science Park, one of Europe's leading locations for science and technology companies, continues to expand as firms move into the newly refurbished Hayakawa Building.

BioIVT to Provide Rare Biosamples for the FNIH Biomarkers Consortium Neurodegenerative Disease Project

BioIVT is sourcing matched sets of cerebrospinal fluid, serum, and plasma from donors afflicted with ALS to further research of neurofilament in the blood as a biomarker for early stages of neurodegeneration.


More within